Pristiq Tablet, Extended Release
Product Images NDC 0008-1222

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pristiq (NDC 0008-1222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pristiq 01)

FDA Label Image

Figure 1 (Pristiq 02)

This text provides pharmacokinetic information about the effect of renal and hepatic impairment, as well as the population characteristics of gender and age on drug exposure. The data includes geometric mean ratios for Cmax and AUC, as well as confidence intervals. The information can be used to adjust drug dosing in patients with renal and hepatic impairment, and for different age and gender groups. The values in the table represent the percentage change relative to the reference case.*

FDA Label Image

Figure 2 (Pristiq 03)

This text appears to be a table showing the change in PK (pharmacokinetics) due to CYP3A4 inhibitors, specifically Ketoconazole, with the values being the geometric mean ratio (90% confidence interval). There are two values shown for Ketoconazole, possibly for different doses or time points. The last row shows a reference value and the change relative to that reference. The meaning and context of the table cannot be determined with this limited information.*

FDA Label Image

Figure 3 (Pristiq 04)

This appears to be a report that includes information on changes in the activity of certain drugs due to interactions with other drugs. The report includes the names of the drugs involved, the type of substrate they are (CYP2D6 or CYP3A4), and various measurements such as Cmax and AuC. Additionally, there are two sections titled "Results for tamoxifen active metabolite" and "Results for anpiprazole active metabolite." Overall, without further context or knowledge in the field, the report is difficult to interpret beyond this level of detail.*

FDA Label Image

Figure 4 (Pristiq 05)

This is a graph showing the estimated proportion of patients with relapse over time for those taking either PRISTIQ50mg or a placebo. The x-axis represents the time to relapse in days from randomization, while the y-axis shows the proportion of patients with relapse in percentage. The graph indicates that fewer patients taking PRISTIQ50mg experienced relapse compared to those taking the placebo.*

FDA Label Image

Figure 5 (Pristiq 06)

FDA Label Image

Logo (Pristiq 07)

This is a description for the product distributor of Wyeth Pharmaceuticals LLC that is a subsidiary of Pfizer Inc. based in Philadelphia, PA 19101.*

FDA Label Image

Logo (Pristiq 08)

This text is a statement of the company distributing a product, specifically Wyeth Pharmaceuticals LLC, which is a subsidiary of Pfizer Inc located in Philadelphia, PA 19101.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack Carton)

This is a description of Pristiq® extended-release tablets manufactured in Singapore. The tablets are available in 50mg and are equivalent to 76mg of desvenlafaxine succinate. Some information is illegible due to errors.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack)

This is a medication guide for Pristiq®, a type of antidepressant medication. The tablets are extended-release and come in either 50mg or 100mg doses. They are packaged in Redipak strips of 10 tablets each, with 10 strips per container. The medication guide advises users that each tablet contains 76mg desvenlafaxine succinate which is equivalent to 50mg desvenlafaxine, and reminds users to refer to the package insert for dosage instructions. It also cautions that the package is designed for multiple dispensing rather than household use, and should be stored within the temperature range of 20-25°C (68-77°F), although excursions to 15°-30°C (59-86°F) are permitted. The medication is manufactured in Singapore and is distributed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

This is a medication description for desvenlafaxine succiate, which is sold under the brand name Pristiq®. The tablets contain 70 mg of the active ingredient and are equivalent to 50 mg of desvenlafaxine. The medication guide is included while dispensing. The usual dosage information can be found on the package insert. The tablets are extended-release and should be stored between 20° to 25°C (68° to 77°F), with excursions permitted up to 30°C (86°F). This medication is distributed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. This is a prescription medication with 30 tablets in each package. It is made in Singapore.*

FDA Label Image

Principal Display Panel (100 mg Tablet Blister Pack Carton)

This is a description of a medication called Pristiq, which contains 152mg desvenlafaxine succinate, equivalent to 100mg desvenlafaxine, which is an extended-release tablet. It is intended to treat depression and anxiety. The usual dosage can be found in the package insert, and it should be stored between 20° to 25°C (68° to 77°F). The medication should always be dispensed with a medication guide, and the package has 30 unit of use tablets. It should be distributed by Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc, in Philadelphia. It is made in Singapore and has a UPC 80% measurement of 5.5mm.*

FDA Label Image

Principal Display Panel (100 mg Tablet Blister Pack)

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Pristiq is a medication that comes in a blister pack containing 10 strips of 10 extended-release tablets, with a total of 100 tablets in the package. It is a desvenlafaxine medication designed to regulate mood swings and is only available via a prescription. This medication should be kept at controlled room temperature between 20°C to 25°C or 68°F to 77°F. Each tablet contains 152 mg desvenlafaxine and is equivalent to 100 mg desvenlafaxine Succinate, as shown in the medication guide, pharmacies should provide with this medication.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

This is a medication guide for Pristiq, a drug with each tablet containing 38mg of desvenlafaxine succinate equivalent to 25mg of desvenlafaxine. The standard dosage is not provided in this guide, and the tablets should be stored between 20-25°C with limited excursions to between 15-30°C. The medication is distributed by Wyeth Pharmaceuticals LLD, a subsidiary of Pfizer Inc. The drug is made in Singapore and intended to be dispensed as a unit. This medication guide is only for prescription use, and a National Drug Code (NDC) of 0008-1210-30 is provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.